Filters

Prescrire international

Showing results (231-240 of 1,424) with videos related to

Pageof 143
Sort By:
Prescrire International|December 15, 2006
Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term
Prescrire International|November 30, 2006
Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue
Prescrire International|November 30, 2006
Oseltamivir: cutaneous and neurological adverse effects in children
Prescrire International|November 30, 2006
Pharmacological prevention of migraine: to be considered case by case
Prescrire International|July 10, 2009
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks
Prescrire International|July 10, 2009
Sorafenib: new indication. For some patients with liver cancer
Prescrire International|July 10, 2009
Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures
Prescrire International|July 10, 2009
Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil
Prescrire International|May 12, 2010
Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option
Prescrire International|May 12, 2010
Cetirizine and loratadine: minimal risk of QT prolongation
Pageof 143

Showing results (231-240 of 1,424) with videos related to

Sort By:
Pageof 143
Prescrire International|December 15, 2006
Inhaled human insulin: new drug. No short-term advantages, too many unknowns in the long term
Prescrire International|November 30, 2006
Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue
Prescrire International|November 30, 2006
Oseltamivir: cutaneous and neurological adverse effects in children
Prescrire International|November 30, 2006
Pharmacological prevention of migraine: to be considered case by case
Prescrire International|July 10, 2009
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks
Prescrire International|July 10, 2009
Sorafenib: new indication. For some patients with liver cancer
Prescrire International|July 10, 2009
Rimonabant: marketing authorization suspended... at last: withdrawal. Half-measures
Prescrire International|July 10, 2009
Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil
Prescrire International|May 12, 2010
Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option
Prescrire International|May 12, 2010
Cetirizine and loratadine: minimal risk of QT prolongation
Pageof 143
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us